The Brosius laboratory focuses on how glucose uptake and transporter expression promote specific cellular signaling responses that lead to physiologic (antiapoptotic, antihypertensive) or pathophysiologic (diabetic nephropathy) responses. More recently, focus has broadened to utilize systems biology and translational approaches in the pursuit of effective treatments and biomarkers for diabetic complications. The laboratory uses a broad array of molecular, cell biological and integrative techniques with a concentrated approach on transgenic and knockout mouse models. The laboratory is one of 12 centers that participate in the NIH sponsored Animal Models of Diabetic Complications Consortium.
Link to PubMed Citations
Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M., Feldman EL, Pennathur S, Brosius FC III. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol, 2008 Oct; 295(4):F1070-81.
Sullivan KA, Hayes JM, Wiggin TD, Backus C, Oh SS, Lentz SI, Brosius FC III, Feldman EL. Mouse models of diabetic neuropathy, Neurobiol Dis. 2007;: 276-85.
Atkins KB, Prezkopf A, Park JL, Saha J, Duquaine D, Olson AL, Charron MJ, Brosius FC III. . The GLUT4 facilitative glucose transporter prevents enhanced agonist-induced vascular reactivity and MYPT1 phosphorylation in hypertensive mouse aorta, Am J Physiol, 2007. 293:H402-8.
Reddy GR, Pushpanathan MJ, Ransom RF, Holzman LB, Brosius FC III, Diakonova M, Mathieson P, Saleem MA, List EO, Kopchick JJ, Frank SJ, Menon RK. Identification of the glomerular podocyte as a target for growth hormone action, Endocrinology, 2007; 148:2045-55.
Duan SD, Ivashchenko CY, Whitesall SE, D’Alecy LG, Duquaine DC, Brosius FC III, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, Mortensen RM. Hypotension, lipodystrophy, and insulin resistance in generalized PPAR- γ deficient mice rescued from embryonic lethality, J Clin Invest, 2007; 117:812-22.
Brosius FC III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, Pennathur S, Smith GL, Wilson PW. Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease. A Science Advisory From the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group Developed in Collaboration With the National Kidney Foundation. Circulation. 2006; 48:751-5 (also published in Hypertension 2006; 48:751-5).
Siu BB, Saha J, Smoyer WE, Sullivan KA, Brosius FC III. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention of by lipoic acid treatment, BMC Nephrology 15 Mar 2006 ).
Zhou, J., Deo, B., Hosoya, K., Terasaki, T., Brosius, F.C., Obrosova, I. , and Kumagai, A.K. Increased JNK Phosphorylation and oxidative stress in response to increased glucose flux through increased GLUT1 expression in rat retinal endothelial cells. Invest Ophthalmol Vis Sci. 2005; 46:3403-10.
Park JL, Loberg RD, Duquaine D, Zhang H, Deo BK, Ardanaz N, Coyle J, Atkins KB, Schin M, Charron MJ, Kumagai AK, Pagano PJ, Brosius FC III. . The GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist-induced vascular reactivity in mouse aorta. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005; 25: 1596-1602.
Breyer MD, Bottinger E, Brosius FC, Coffman TM, Fogo A, Harris RC, Heilig CW, Sharma K. Diabetic nephropathy: Of mice and men. Adv Chronic Kidney Dis. 2005; 12:128-45.
Brosius FC III, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol. 2005; 20:447-51.
Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse Models of Diabetic Nephropathy. J Am Soc Nephrol. 2005; 16:27 -45
Atkins KB, Northcott C, Watts S, Brosius FC III. Effect of PPAR g ligands on hypertension and vascular smooth muscle marker expression, Am J Physiol. 2005; 288:H235-H243.
Vega-Warner V, Ransom RF, Brosius FC, Smoyer WE. Induction of Podocyte Antioxidant Enzymes Precedes Injury by Puromycin Aminonucleoside In Vitro, Kidney International, 2004; 66:1881-9.
Shen H, Smith DE , Keep RF, Brosius FC III. Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in rat brain. Mol Pharm 2004; 1:248-256.
Park JL, Heilig CW, Brosius FC III. GLUT1-Deficient Mice Exhibit Impaired Endothelium-Dependent Vascular Relaxation, Eur J Pharmacol. 2004; 496:213-4.
Slovut DP, Mehta SH, Dorrance AM, Brosius FC, Watts SW, Webb RC. Increased vascular sensitivity and connexin 43 expression after sympathetic denervation. Cardiovas Res, 2004, 62:388-96.